These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 23406555)

  • 1. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
    Provenzano A; Kurian S; Abraham J
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors.
    Mills JN; Rutkovsky AC; Giordano A
    Curr Opin Pharmacol; 2018 Aug; 41():59-65. PubMed ID: 29719270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutical strategies in metastatic hormone-dependent breast cancer].
    Vilquin P; Cohen P; Maudelonde T; Tredan O; Treilleux I; Bachelot T; Heudel PE
    Bull Cancer; 2015 Apr; 102(4):367-80. PubMed ID: 25799877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
    Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.
    Gnant M
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1579-89. PubMed ID: 23253223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming resistance: targeting the PI3K/mTOR pathway in endocrine refractory breast cancer.
    Butt AJ
    Cancer Biol Ther; 2011 Jun; 11(11):947-9. PubMed ID: 21577052
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting endocrine resistance: is there a role for mTOR inhibition?
    Sheri A; Martin LA; Johnston S
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone resistance and its modulation in breast cancer].
    Kahán Z; Thurzó L
    Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
    Ziauddin MF; Hua D; Tang SC
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):791-807. PubMed ID: 24944077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.
    Fan W; Chang J; Fu P
    Future Med Chem; 2015 Aug; 7(12):1511-9. PubMed ID: 26306654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.